Edgewise Therapeutics closed at $37.53 on Nov 4, down 0.40%, 22.4% below its 52-week closing high. Volume of 1.1M shares was 0.79× its 20-day average (below normal).
Split-adjusted performance: -6.2% over one month, +1.5% over six months, +108.8% over one year.
Short interest was 11.8M shares at the Oct 15 settlement, up 4.7% from the prior report (16.7% of float, 8.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| EWTXEdgewise Therapeutics | $37.53 | −0.40% | +1.5% | — | — | — | $4.08B | |
| ABCLAbCellera Biologics | $12.28 | +0.82% | +143.7% | −76.3% | −1368.6% | — | $3.98B | Compare |
| LQDALiquidia | $47.38 | +12.27% | +12.4% | +1842.7% | 43.5% | 30.6 | $4.24B | Compare |
| TNGXTango Therapeutics | $23.18 | +0.04% | −1.9% | −100.0% | — | — | $3.91B | Compare |
| ARQTArcutis Biotherapeutics | $34.05 | +6.41% | +40.9% | +59.3% | 11.6% | 150.1 | $4.28B | Compare |
| XENEXenon Pharmaceuticals | $39.19 | +2.51% | −33.1% | — | — | — | $3.80B | Compare |
| DFTXDefinium Therapeutics | $32.70 | −2.13% | +39.6% | — | — | — | $4.39B | Compare |
| PBLSParabilis Medicines | $30.36 | +3.79% | — | — | −45239.9% | — | $3.75B | Compare |
| ACADAcadia Pharmaceuticals | $21.47 | +4.38% | 0.0% | +16.4% | 10.2% | 9.7 | $3.70B | Compare |
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
